213 related articles for article (PubMed ID: 22899854)
1. Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer.
Reebye V; Querol Cano L; Lavery DN; Brooke GN; Powell SM; Chotai D; Walker MM; Whitaker HC; Wait R; Hurst HC; Bevan CL
Mol Endocrinol; 2012 Oct; 26(10):1694-706. PubMed ID: 22899854
[TBL] [Abstract][Full Text] [Related]
2. The co-chaperone p23 promotes prostate cancer motility and metastasis.
Cano LQ; Lavery DN; Sin S; Spanjaard E; Brooke GN; Tilman JD; Abroaf A; Gaughan L; Robson CN; Heer R; Mauri F; de Rooij J; Driouch K; Bevan CL
Mol Oncol; 2015 Jan; 9(1):295-308. PubMed ID: 25241147
[TBL] [Abstract][Full Text] [Related]
3. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.
Ni L; Yang CS; Gioeli D; Frierson H; Toft DO; Paschal BM
Mol Cell Biol; 2010 Mar; 30(5):1243-53. PubMed ID: 20048054
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of HSP90 by protein kinase A is essential for the nuclear translocation of androgen receptor.
Dagar M; Singh JP; Dagar G; Tyagi RK; Bagchi G
J Biol Chem; 2019 May; 294(22):8699-8710. PubMed ID: 30992362
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.
Chan SC; Li Y; Dehm SM
J Biol Chem; 2012 Jun; 287(23):19736-49. PubMed ID: 22532567
[TBL] [Abstract][Full Text] [Related]
6. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
Saporita AJ; Ai J; Wang Z
Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
[TBL] [Abstract][Full Text] [Related]
7. High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance.
Simpson NE; Lambert WM; Watkins R; Giashuddin S; Huang SJ; Oxelmark E; Arju R; Hochman T; Goldberg JD; Schneider RJ; Reiz LF; Soares FA; Logan SK; Garabedian MJ
Cancer Res; 2010 Nov; 70(21):8446-56. PubMed ID: 20847343
[TBL] [Abstract][Full Text] [Related]
8. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
Buchanan G; Ricciardelli C; Harris JM; Prescott J; Yu ZC; Jia L; Butler LM; Marshall VR; Scher HI; Gerald WL; Coetzee GA; Tilley WD
Cancer Res; 2007 Oct; 67(20):10087-96. PubMed ID: 17942943
[TBL] [Abstract][Full Text] [Related]
9. Mini-review: Foldosome regulation of androgen receptor action in prostate cancer.
Cano LQ; Lavery DN; Bevan CL
Mol Cell Endocrinol; 2013 Apr; 369(1-2):52-62. PubMed ID: 23395916
[TBL] [Abstract][Full Text] [Related]
10. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
Ai J; Wang Y; Dar JA; Liu J; Liu L; Nelson JB; Wang Z
Mol Endocrinol; 2009 Dec; 23(12):1963-72. PubMed ID: 19855091
[TBL] [Abstract][Full Text] [Related]
11. The cochaperone SGTA (small glutamine-rich tetratricopeptide repeat-containing protein alpha) demonstrates regulatory specificity for the androgen, glucocorticoid, and progesterone receptors.
Paul A; Garcia YA; Zierer B; Patwardhan C; Gutierrez O; Hildenbrand Z; Harris DC; Balsiger HA; Sivils JC; Johnson JL; Buchner J; Chadli A; Cox MB
J Biol Chem; 2014 May; 289(22):15297-308. PubMed ID: 24753260
[TBL] [Abstract][Full Text] [Related]
12. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
13. Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta.
EcheverrÃa PC; Mazaira G; Erlejman A; Gomez-Sanchez C; Piwien Pilipuk G; Galigniana MD
Mol Cell Biol; 2009 Sep; 29(17):4788-97. PubMed ID: 19581287
[TBL] [Abstract][Full Text] [Related]
14. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
[TBL] [Abstract][Full Text] [Related]
15. The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells.
Dar JA; Masoodi KZ; Eisermann K; Isharwal S; Ai J; Pascal LE; Nelson JB; Wang Z
J Steroid Biochem Mol Biol; 2014 Sep; 143():473-80. PubMed ID: 24662325
[TBL] [Abstract][Full Text] [Related]
16. Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis.
DePaolo JS; Wang Z; Guo J; Zhang G; Qian C; Zhang H; Zabaleta J; Liu W
Oncotarget; 2016 Nov; 7(44):71417-71428. PubMed ID: 27659526
[TBL] [Abstract][Full Text] [Related]
17. Berberine suppresses androgen receptor signaling in prostate cancer.
Li J; Cao B; Liu X; Fu X; Xiong Z; Chen L; Sartor O; Dong Y; Zhang H
Mol Cancer Ther; 2011 Aug; 10(8):1346-56. PubMed ID: 21613449
[TBL] [Abstract][Full Text] [Related]
18. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
Cha TL; Qiu L; Chen CT; Wen Y; Hung MC
Cancer Res; 2005 Mar; 65(6):2287-95. PubMed ID: 15781642
[TBL] [Abstract][Full Text] [Related]
19. Glyceraldehyde-3-phosphate dehydrogenase enhances transcriptional activity of androgen receptor in prostate cancer cells.
Harada N; Yasunaga R; Higashimura Y; Yamaji R; Fujimoto K; Moss J; Inui H; Nakano Y
J Biol Chem; 2007 Aug; 282(31):22651-61. PubMed ID: 17553795
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of telomerase-associated chaperone proteins in prostatic intraepithelial neoplasia and carcinomas.
Elmore LW; Forsythe R; Forsythe H; Bright AT; Nasim S; Endo K; Holt SE
Oncol Rep; 2008 Sep; 20(3):613-7. PubMed ID: 18695913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
